Posted by Kizzie2 on October 16, 2011, at 12:54:28
In reply to Long term AD use effects, posted by Kizzie2 on October 16, 2011, at 12:09:54
Apologies - I meant to add the study below to my original question. I have tried to google some of the content but still struggling to work out what it *actually* means. The reason I am asking these questions is because I am now in my 13th year on AD's with no immediate prospect of being able to come off - although I have reduced the dose. I am very keen to find out if a/ there are long term effects I need to be concerned about and b/ whether there is anything I can do to minimise them with diet/healthy living/mindfulness/meditation (partic related to any brain or emotional impacts ). Thank you !! for any advice.
---------------------------
Long-term clomipramine treatment upregulates forebrain acetylcholine muscarinic receptors, and reduces behavioural sensitivity to scopolamine in mice.AuthorsTsukagoshi H, et al. Show all Journal
J Pharm Pharmacol. 2000 Jan;52(1):87-92.Affiliation
Department of Anesthesiology and Reanimatology, Gunma University School of Medicine and Hospital, Maebashi, Japan.Abstract
We have investigated the effects of long-term treatment with clomipramine, a tricyclic antidepressant, on central muscarinic acetylcholine receptors (mAChR) in mice. Repeated clomipramine administration resulted in an increase in the forebrain receptor density value (Bmax) for [3H]quinuclidinyl benzilate, a muscarinic ligand (P < 0.05), that was dependent on dose per administration (saline or 5, 10, or 20 mg kg(-1) once a day for 7 days) and number of days treated (20 mg kg(-1) for 1, 3, 5, or 7 days). No change in apparent affinity (defined as the reciprocal of the dissociation constant) (KD) occurred. Seven daily treatments with clomipramine (saline or 5, 10, or 20 mg kg(-1)) reduced hyperlocomotion induced by scopolamine (0.5 mg kg(-1), s.c.) dose-dependently, and the effect of 20 mg kg(-1) clomipramine was significant (P < 0.05). These results suggest that an upregulation of mAChR is produced by repeated clomipramine administration, and such a change is responsible for the decreased sensitivity to the muscarinic antagonist scopolamine.
poster:Kizzie2
thread:999894
URL: http://www.dr-bob.org/babble/20111016/msgs/999898.html